Yüklüyor......
Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
Inhibitors of sodium–glucose cotransporter 2 (SGLT2) have emerged as practice-changing treatments for patients with type 2 diabetes, reducing both the risk of cardiovascular events and kidney events. However, regarding the latter, caution is warranted, as these kidney endpoints are defined using glo...
Kaydedildi:
| Yayımlandı: | J Clin Med |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7291210/ https://ncbi.nlm.nih.gov/pubmed/32466262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9051603 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|